Science Explorer Back to mapMap
Discussion
Institution · Cyclacel Pharmaceuticals (United Kingdom)

Most cited papers from Cyclacel Pharmaceuticals (United Kingdom)

Cyclacel Pharmaceuticals (United Kingdom)

What are the most cited papers from Cyclacel Pharmaceuticals (United Kingdom)?

The most cited paper from Cyclacel Pharmaceuticals (United Kingdom) is "In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)" (Steven J. McClue, David G. BLAKE, Rosemary G. Clarke et al., 2002), with 367 citations. Next come "Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients" (336) and "An in vitro model of angiogenesis: Basic features" (311).

Showing 50 of 60 papers. Every paper with more than 43 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) Steven J. McClue, David G. BLAKE, Rosemary G. Clarke et al. · International Journal of Cancer Open access 9 Oct 2002 367
2 Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients Maurizio Scaltriti, Pieter J.A. Eichhorn, Javier Cortés et al. · Proceedings of the National Academy of Sciences Open access 14 Feb 2011 336
3 An in vitro model of angiogenesis: Basic features Eileen Bishop, Graham T. Bell, Stephen Bloor et al. · Angiogenesis Dec 1999 311
4 Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II–Dependent Transcription and Down-regulation of Mcl-1 David E. MacCallum, Jean Melville, Sheelagh Frame et al. · Cancer Research Open access 15 Jun 2005 288
5 A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days Charlotte Benson, Jeff D White, Johann Sebastian De Bono et al. · British Journal of Cancer Open access 19 Dec 2006 263
6 Aurora kinase inhibitors: Progress towards the clinic Madhu Kollareddy, Daniella I. Zheleva, Petr Džubák et al. · Investigational New Drugs Open access 17 Feb 2012 243
7 Diketopiperazines in peptide and combinatorial chemistry Peter M. Fischer · Journal of Peptide Science 2003 192
8 Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma Noopur S Raje, Shaji Kunnathu Kumar, Teru Hideshima et al. · Blood Open access 13 Apr 2005 185
9 Structure–activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin Peter M. Fischer, Nikolai Zhelev, S. Wang et al. · Journal of Peptide Research Feb 2000 171
10 Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies Christophe Le Tourneau, Sandrine J. Faivre, Valérie Laurence et al. · European Journal of Cancer 7 Sep 2010 167
11 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity Shudong Wang, Christopher K. Meades, Gavin Wood et al. · Journal of Medicinal Chemistry Open access 7 Feb 2004 153
12 Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics Peter M. Fischer, David Philip Lane · Current Medicinal Chemistry Dec 2000 148
13 Structure of Free MDM2 N-terminal Domain Reveals Conformational Adjustments that Accompany p53-binding Stanislava Uhrı́nová, Dušan Uhrı́n, Helen Powers et al. · Journal of Molecular Biology Jun 2005 144
14 A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival Azra J. Alvi, Belinda Austen, Victoria Weston et al. · Blood 4 Feb 2005 133
15 In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202 Florence I. Raynaud, Steven R. Whittaker, Peter M. Fischer et al. · Clinical Cancer Research Open access Jul 2005 131
16 Cellular Delivery of Impermeable Effector Molecules in the Form of Conjugates with Peptides Capable of Mediating Membrane Translocation Peter M. Fischer, Eberhard Krausz, David Philip Lane · Bioconjugate Chemistry 24 Oct 2001 126
17 Recent progress in the discovery and development of cyclin-dependent kinase inhibitors Peter M. Fischer, Athos Gianella-Borradori · Expert Opinion on Investigational Drugs Apr 2005 123
18 The Design, Synthesis and Application of Stereochemical and Directional Peptide Isomers: A Critical Review Peter M. Fischer · Current Protein and Peptide Science Oct 2003 122
19 CDK inhibitors in clinical development for the treatment of cancer Peter M. Fischer, Athos Gianella-Borradori · Expert Opinion on Investigational Drugs Jun 2003 118
20 AURORA KINASES: STRUCTURE, FUNCTIONS AND THEIR ASSOCIATION WITH CANCER Madhu Kollareddy, Petr Džubák, Daniella I. Zheleva et al. · Biomedical Papers Open access Jun 2008 116
21 The Design of Drug Candidate Molecules as Selective Inhibitors of Therapeutically Relevant Protein Kinases Peter M. Fischer · Current Medicinal Chemistry Jun 2004 115
22 Progress in the Discovery of Polo-like Kinase Inhibitors Campbell McInnes, Mokdad Mezna, Peter M. Fischer · Current Topics in Medicinal Chemistry 29 Mar 2005 111
23 Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor Ida Iurisci, Elisabeth Filipski, Jens Reinhardt et al. · Cancer Research 15 Nov 2006 111
24 Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS Su Ying Wu, Iain W. McNae, George A. Kontopidis et al. · Structure Open access Apr 2003 105
25 Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents Shudong Wang et al. · Chemistry & Biology Open access Oct 2010 104
26 Discovery ofN-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors Shudong Wang et al. · Journal of Medicinal Chemistry Open access 12 May 2010 102
27 Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance Campbell McInnes, A. Mazumdar, Mokdad Mezna et al. · Nature Chemical Biology Open access 8 Oct 2006 100
28 Update on the molecular biology of mantle cell lymphoma Francesco Bertoni, Andrea Rinaldi, Emanuele Zucca et al. · Hematological Oncology 2006 100
29 Reversal of Collapsing Glomerulopathy in Mice with the Cyclin-Dependent Kinase Inhibitor CYC202 Dana Gherardi, Vivette Denise D’Agati, Te-Hua Tearina Chu et al. · Journal of the American Society of Nephrology May 2004 97
30 NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019 William G. Wierda et al. · Journal of the National Comprehensive Cancer Network 2019 95
31 Bioluminescent imaging of Cdk2 inhibition in vivo Guo-Jun Zhang, Michal Safran, Wenyi Wei et al. · Nature Medicine 2 May 2004 89
32 Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer Sheelagh Frame, Chiara Saladino, Craig MacKay et al. · PLoS ONE Open access 9 Jul 2020 88
33 Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer Wen-Son Hsieh, Ross Andrew Soo, B.K. Peh et al. · Clinical Cancer Research 15 Feb 2009 83
34 Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome Hagop M. Kantarjian, Guillermo Garcia‐Manero, Susan A. O'Brien et al. · Journal of Clinical Oncology Open access 24 Nov 2009 82
35 Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma Lucas Moreno et al. · European Journal of Cancer Open access 8 Jul 2020 80
36 The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A Maria Gloria Luciani, James R. A. Hutchins, Daniella I. Zheleva et al. · Journal of Molecular Biology Jul 2000 74
37 In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas Katia Lacrima, Alessandra Valentini, Chiara Lambertini et al. · Annals of Oncology Open access 26 Apr 2005 73
38 Crystallographic and Mass Spectrometric Characterisation of eIF4E with N7-alkylated Cap Derivatives Christopher John Brown, Iain W. McNae, Peter M. Fischer et al. · Journal of Molecular Biology 16 Jun 2007 73
39 Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma Evon Poon et al. · Journal of Clinical Investigation Open access 5 Oct 2020 71
40 Small-molecule inhibitors of the p53 suppressor HDM2: have protein–protein interactions come of age as drug targets? Peter M. Fischer, David Philip Lane · Trends in Pharmacological Sciences Review 13 May 2004 70
41 Antiviral Activity of CYC202 in HIV-1-infected Cells Emmanuel T. Agbottah, Cynthia de la Fuente, Sergie Nekhai et al. · Journal of Biological Chemistry Open access 6 Nov 2004 70
42 Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe Fabrizio Galimberti, Sarah Thompson, Xi Liu et al. · Clinical Cancer Research Open access 22 Dec 2009 68
43 Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study Hagop M. Kantarjian, Stefan H Faderl, Guillermo Garcia‐Manero et al. · The Lancet Oncology Open access 14 Oct 2012 65
44 Differential Binding of Inhibitors to Active and Inactive CDK2 Provides Insights for Drug Design George A. Kontopidis, Campbell McInnes, Sravan R. Pandalaneni et al. · Chemistry & Biology Open access Feb 2006 65
45 Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors Campbell McInnes, Shudong Wang, Sian Anderson et al. · Chemistry & Biology Open access Apr 2004 63
46 Insights into Cyclin Groove Recognition George A. Kontopidis, Martin J. I. Andrews, Campbell McInnes et al. · Structure Open access Dec 2003 63
47 Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors Shudong Wang, Gavin Wood, Christopher K. Meades et al. · Bioorganic & Medicinal Chemistry Letters Open access 16 Jul 2004 61
48 Highly potent p21WAF1‐derived peptide inhibitors of CDK‐mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A Daniella I. Zheleva, Campbell McInnes, A.‐L. Gavine et al. · Journal of Peptide Research Nov 2002 60
49 Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes Martin J. I. Andrews, Campbell McInnes, George A. Kontopidis et al. · Organic & Biomolecular Chemistry 2004 58
50 Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor Vladimı́r Kryštof, Iain W. McNae, Malcolm D. Walkinshaw et al. · Cellular and Molecular Life Sciences Open access 7 Jul 2005 55

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.